Lexology December 18, 2025
Stakeholders are grappling with the numerous opportunities and risks presented by the convergence of artificial intelligence and tools designed for the development of novel therapeutics and the delivery of health care.
Drug discovery and clinical trials
AI is considered by many as a groundbreaking tool for use in drug discovery and precision medicine. The clinical translation of AI-discovered novel drug-target interactions is rapidly accelerating, with tangible evidence of success emerging across multiple therapeutic areas. Drug developers are using models trained on large data sets to not only identify biological targets that cause disease but to also select potential drug candidates that may interact with those targets. As of 2024, over 70 investigational new drug applications submitted to the U.S. FDA...
Today's Sponsors
Today's Sponsor